Licence Agreement with CWRU (Supplementary Announcement)

On November 24, 2022 Chimeric Therapeutics (ASX: CHM, "Chimeric"), a clinical-stage cell therapy company and an Australian leader in cell therapy, reported an additional information regarding an exclusive license agreement with Case Western Reserve University (CWRU) for the CORE-NK platform, invented by Dr David Wald (Press release, Chimeric Therapeutics, NOV 24, 2022, View Source [SID1234624413]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The CORE-NK platform uses a novel, proprietary genetically-modified feeder cell line to activate and expand universal off-the-shelf allogeneic NK cell products derived from healthy donors. The expanded CORE-NK cells exhibit enhanced cytotoxicity, metabolism, and expression of activating receptors compared to fresh, activated NK cells.

Under the agreement, Chimeric gains exclusive global rights to the CORE-NK platform for oncology, where Chimeric and CWRU are currently advancing multiple product candidates in Dr Wald’s laboratory under the Sponsored Research Agreement announced on 2 November 2022. Chimeric also receives exclusive global rights to the CORE-NK platform for immune disorders and viral infectious diseases.

Chimeric’s exclusive global license from CWRU covers patent rights, knowhow, and biological materials in relation to therapeutic products for the NKF feeder cell line and CORE-NK manufacturing process in the fields of use, including access to regulatory documents for the first-in-human Phase 1 trial of CHM 0201.

The agreement is effective immediately, with a minimum term of 20 years (or until the later expiry of relevant patents or licenced product terms). The agreement may be terminated due to unresolved default of payment or performance by either party, or at the sole discretion of Chimeric. Upfront fees associated with the license agreement are not material and will be funded entirely from existing cash reserves. The agreement includes industry standard development milestones, patent costs, maintenance fees, and royalties on commercial net sales. Under the agreement, each party owns all of the rights, title and interest in results developed by them. Chimeric is entitled to use jointly developed results under the terms of the For personal use only agreement.